We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Eye Care

Journal Scan / Research · July 30, 2020

Cost–Benefit Analysis of VEGF Inhibitors for Neovascular AMD

American Journal of Ophthalmology


Additional Info

American Journal of Ophthalmology
A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States
Am J Ophthalmol 2020 Jul 16;[EPub Ahead of Print], GC Brown, MM Brown, SB Rapuano, D Boyer

Further Reading